JP2012524733A5 - - Google Patents

Download PDF

Info

Publication number
JP2012524733A5
JP2012524733A5 JP2012506340A JP2012506340A JP2012524733A5 JP 2012524733 A5 JP2012524733 A5 JP 2012524733A5 JP 2012506340 A JP2012506340 A JP 2012506340A JP 2012506340 A JP2012506340 A JP 2012506340A JP 2012524733 A5 JP2012524733 A5 JP 2012524733A5
Authority
JP
Japan
Prior art keywords
composition
vaccine
immunogenic
antigen
mycobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012506340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524733A (ja
JP5839361B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2010/000054 external-priority patent/WO2010121618A1/en
Publication of JP2012524733A publication Critical patent/JP2012524733A/ja
Publication of JP2012524733A5 publication Critical patent/JP2012524733A5/ja
Application granted granted Critical
Publication of JP5839361B2 publication Critical patent/JP5839361B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012506340A 2009-04-24 2010-04-23 再活性化を予防する結核tbワクチン Expired - Fee Related JP5839361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200900539 2009-04-24
DKPA200900539 2009-04-24
PCT/DK2010/000054 WO2010121618A1 (en) 2009-04-24 2010-04-23 A tuberculosis tb vaccine to prevent reactivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015127000A Division JP6215260B2 (ja) 2009-04-24 2015-06-24 再活性化を予防する結核tbワクチン

Publications (3)

Publication Number Publication Date
JP2012524733A JP2012524733A (ja) 2012-10-18
JP2012524733A5 true JP2012524733A5 (https=) 2013-06-06
JP5839361B2 JP5839361B2 (ja) 2016-01-06

Family

ID=43010694

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012506340A Expired - Fee Related JP5839361B2 (ja) 2009-04-24 2010-04-23 再活性化を予防する結核tbワクチン
JP2015127000A Active JP6215260B2 (ja) 2009-04-24 2015-06-24 再活性化を予防する結核tbワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015127000A Active JP6215260B2 (ja) 2009-04-24 2015-06-24 再活性化を予防する結核tbワクチン

Country Status (17)

Country Link
US (2) US9074001B2 (https=)
EP (1) EP2421557B1 (https=)
JP (2) JP5839361B2 (https=)
KR (2) KR20170072366A (https=)
CN (2) CN102413837B (https=)
AU (1) AU2010238943B9 (https=)
BR (1) BRPI1006452A2 (https=)
CA (1) CA2759583C (https=)
DK (1) DK2421557T3 (https=)
ES (1) ES2714383T3 (https=)
HK (1) HK1204549A1 (https=)
IL (1) IL215591A (https=)
MX (2) MX2011011186A (https=)
PL (1) PL2421557T3 (https=)
TR (1) TR201903223T4 (https=)
WO (1) WO2010121618A1 (https=)
ZA (1) ZA201108564B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
AU2009273130B2 (en) * 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
CA2731549C (en) 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
PL2661253T3 (pl) * 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
DK2802345T3 (en) 2012-01-12 2018-04-30 Archivel Farma Sl MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
JP6470179B2 (ja) * 2012-10-23 2019-02-13 スタテンス セールム インスティトゥート 結核菌(m.tuberculosis)ワクチン
KR20150127587A (ko) * 2013-03-15 2015-11-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 결핵의 예방 또는 치료를 위한 합성 면역원
AU2014365971B2 (en) * 2013-12-16 2021-02-04 Statens Serum Institut Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
WO2015104380A1 (en) * 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
US10004793B2 (en) 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
CN104151433A (zh) * 2014-08-11 2014-11-19 兰州大学 一种结核分枝杆菌融合蛋白及其制备方法和应用
CN104225591A (zh) * 2014-09-15 2014-12-24 兰州大学 一种免疫佐剂及含有该免疫佐剂的疫苗
JP2019521095A (ja) * 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
CA3098015A1 (en) 2018-04-26 2019-10-31 Children's National Medical Center Mycobacterial antigen compositions and methods of use
CN110423279B (zh) * 2019-06-20 2021-07-27 扩增生物科技(北京)有限公司 结核分枝杆菌重组融合蛋白eecc及其制备方法和应用
CN115598041B (zh) * 2021-07-07 2025-08-19 中国科学院微生物研究所 结核鉴别诊断细胞因子及其在结核感染风险评估中的应用
KR102577332B1 (ko) * 2021-12-29 2023-09-11 재단법인 오송첨단의료산업진흥재단 항원성 및 안정성이 개선된 항원을 포함하는 잠복결핵 진단용 조성물
KR20250082868A (ko) 2023-11-30 2025-06-09 서울대학교산학협력단 분비형 코리스메이트 뮤테이즈 (Rv1885c)가 약화된 Mycobacterium bovis BCG 균주, 이를 포함하는 백신용 조성물 및 이의 용도
CN117777259B (zh) * 2024-02-23 2024-06-07 上海科新生物技术股份有限公司 检测结核感染的抗原组合物、试剂盒及其应用
CN120192426B (zh) * 2025-03-04 2025-11-11 江西澄实生物科技有限公司 一种预防沙门氏菌感染的疫苗及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
CN1105236A (zh) * 1993-11-13 1995-07-19 丛繁滋 肺结核防传播及治疗用气雾剂及其制备方法
CN1051234C (zh) * 1994-04-15 2000-04-12 焦安国 一种治疗结核病的药物
PT832093E (pt) 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expressão de lipoproteínas
US6338852B1 (en) * 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
JP5010079B2 (ja) 1999-07-13 2012-08-29 スタテンズ セーラム インスティテュート マイコバクテリウム・ツベルクローシスesat−6遺伝子ファミリーベースの結核ワクチン及び診断法
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
GB0030368D0 (en) 2000-12-13 2001-01-24 Inst Of Molecul & Cell Biology Dormancy-induced mycobacterium proteins
NZ526807A (en) * 2001-01-08 2005-03-24 Isis Innovation Assay to determine efficacy of treatment for mycobacterial infection
ATE535600T1 (de) * 2002-04-05 2011-12-15 Pasteur Institut Identifizierung der virulenz-assoziierten region rd1, die die entwicklung von verbesserten impstoffen mit m. microti ermöglicht
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004067718A2 (en) 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
EP2226332A1 (en) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
CN102220357B (zh) * 2004-11-16 2013-12-25 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
BRPI0606165A2 (pt) 2005-01-05 2009-06-02 Isis Innovation método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
BRPI0612833A2 (pt) 2005-06-23 2010-11-30 Statens Seruminstitut composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras
EP2040745B1 (en) * 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
AU2009273130B2 (en) 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods

Similar Documents

Publication Publication Date Title
JP2012524733A5 (https=)
JP6470179B2 (ja) 結核菌(m.tuberculosis)ワクチン
CA2759583C (en) A tuberculosis tb vaccine to prevent reactivation
US10004793B2 (en) M.tuberculosis vaccines
JP2013507907A5 (https=)
JP2008543890A5 (https=)
CN110506108B (zh) 过表达phoP-phoR的重组BCG
JP2016513078A (ja) 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン
CN101822829B (zh) 一种用于结核病预防的重组卡介苗
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
Lu et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime‐boost regimen with BCG and a DNA vaccine expressing ESAT‐6 and Ag85A fusion protein
JP2015513314A5 (https=)
CN103266119A (zh) 一种结核杆菌三抗原融合基因疫苗及其制备方法和应用
WO2012126149A1 (zh) 结核杆菌融合蛋白及其制备方法和应用
JP5994127B2 (ja) 新規な組換えbcgワクチン
CN101455846A (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
CN108330142A (zh) 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白
US10406219B2 (en) Multivalent Brucella vaccine for protection against mycobacterial infections and methods of using the same
CN111948387B (zh) 结核分枝杆菌抗原蛋白Rv1485在制备结核疫苗中的应用
US9562080B2 (en) Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of lyme disease vaccine
CN102772795B (zh) 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
CN104371013B (zh) 牛分枝杆菌cfp-10的迟发型变态反应抗原表位多肽及其应用
RU2776479C1 (ru) Живая пробиотическая вакцина, содержащая консервативные эпитопы вируса гриппа А (LAH+4M2e), для профилактики гриппозной инфекции
CN111948399A (zh) 结核分枝杆菌抗原蛋白Rv1705c及其T细胞表位肽的应用
WO2024196719A2 (en) Membrane vesicles comprising multiple influenza antigens for vaccines